Pharmaceutical Preparations · DE · CIK 1710072
Edgewise Therapeutics discovers and develops precision medicines targeting key muscle proteins for serious muscle diseases
Comparable business profile · signals at a glance
In the 90 days to Mar 31, 2026: 2 sold $4.6M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 31, 2026 | Donovan Joanne M.CMO | Sell | 21,338 | $32.12 | $685K |
| Mar 27, 2026 | Donovan Joanne M.CMO | Sell | 9,623 | $30.98 | $298K |
| Mar 27, 2026 | Donovan Joanne M.CMO | Sell | 6,735 | $30.98 | $209K |
| Jan 21, 2026 | Edris BadreddinDirector | Sell | 66,477 | $29.44 | $2.0M |
| Jan 21, 2026 | Edris BadreddinDirector | Sell | 17,236 | $29.44 | $507K |
| Jan 21, 2026 | Edris BadreddinDirector | Sell | 13,690 | $29.44 | $403K |
| Jan 21, 2026 | Edris BadreddinDirector | Sell | 10,463 | $29.44 | $308K |
| Jan 21, 2026 | Edris BadreddinDirector | Sell | 7,605 | $29.44 | $224K |
| Nov 12, 2025 | Russell Alan JChief Scientific Officer | Sell | 100,000 | $21.12 | $2.1M |
| Nov 11, 2025 | Fox Jonathan CDirector | Buy | 10,700 | $18.64 | $199K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Coverage (30d): 2 reputable articles.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗